Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2022-10-03 00:00:00 ET · period of report 2022-10-03 · accession 0001725160-22-000180 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-10-03 | 2022-10-03 | ZNTL | Epperly Melissa B, | CFO | A - Grant | $0.00 | +50.0K | 297.5K | +20% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-03 | A | A | 50,000 | $0.00 | 297,543 | D | — | — | (F1) Represents restricted stock units ("RSUs") granted by the Issuer under the 2020 Incentive Award Plan, as amended. The RSUs will vest over two years: 1/3 of the RSUs will vest on the first anniversary of the date of grant, and the remaining 2/3 of the RSUs will vest on the second anniversary of the date of grant. (F2) Includes 129 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2022. |